Comparative analysis of remission induction therapy for high-risk MDS and AML progressed from MDS in the MDS200 study of Japan Adult Leukemia Study Group

Yasuyoshi Morita, Akihisa Kanamaru, Yasushi Miyazaki, Daisuke Imanishi, Fumiharu Yagasaki, Mitsune Tanimoto, Kazutaka Kuriyama, Toru Kobayashi, Shion Imoto, Kazunori Ohnishi, Tomoki Naoe, Ryuzo Ohno

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

A total of 120 patients with high-risk myelodysplastic syndrome (MDS) and AML progressed from MDS (MDS-AML) were registered in a randomized controlled study of the Japan Adult Leukemia Study Group (JALSG). Untreated adult patients with high-risk MDS and MDS-AML were randomly assigned to receive either idarubicin and cytosine arabinoside (IDR/Ara-C) (Group A) or low-dose cytosine arabinoside and aclarubicin (CA) (Group B). The remission rates were 64.7% for Group A (33 of 51 evaluable cases) and 43.9% for Group B (29 out of 66 evaluable cases). The 2-year overall survival rates and disease-free survival rates were 28.1 and 26.0% for Group A, and 32.1 and 24.8% for Group B, respectively. The duration of CR was 320.6 days for Group A and 378.7 days for Group B. There were 15 patients who lived longer than 1,000 days after diagnosis: 6 and 9 patients in Groups A and B, respectively. However, among patients enrolled in this trial, intensive chemotherapy did not produce better survival than low-dose chemotherapy. In conclusion, it is necessary to introduce the first line therapy excluding the chemotherapy that can prolong survival in patients with high-risk MDS and MDS-AML.

Original languageEnglish
Pages (from-to)97-103
Number of pages7
JournalInternational journal of hematology
Volume91
Issue number1
DOIs
Publication statusPublished - Jan 2010

Keywords

  • HSCT
  • Induction therapy
  • JALSG MDS200
  • MDS
  • MDS-AML

ASJC Scopus subject areas

  • Hematology

Fingerprint Dive into the research topics of 'Comparative analysis of remission induction therapy for high-risk MDS and AML progressed from MDS in the MDS200 study of Japan Adult Leukemia Study Group'. Together they form a unique fingerprint.

  • Cite this

    Morita, Y., Kanamaru, A., Miyazaki, Y., Imanishi, D., Yagasaki, F., Tanimoto, M., Kuriyama, K., Kobayashi, T., Imoto, S., Ohnishi, K., Naoe, T., & Ohno, R. (2010). Comparative analysis of remission induction therapy for high-risk MDS and AML progressed from MDS in the MDS200 study of Japan Adult Leukemia Study Group. International journal of hematology, 91(1), 97-103. https://doi.org/10.1007/s12185-009-0473-4